For the roughly 1,850 Australians on transplant waiting lists at any one time, the promise of medical science often arrives just too slowly. Transplant Australia estimates that liver and heart recipients can face waits of nine months or more, and not every patient is well enough to survive the surgery when a donor organ finally becomes available. Against that backdrop, a new study from the Massachusetts Institute of Technology deserves serious attention, even if the results so far come only from mice.
Published in the journal Cell Biomaterials, the research describes what the MIT team calls Injected, Self-assembled, Image-guided Tissue Ensembles, or INSITE: a technique in which liver cells known as hepatocytes are mixed with hydrogel microspheres and delivered into the body via ultrasound-guided injection. The spheres have special properties that allow them to act like a liquid when closely packed together, so they can flow through a syringe and then regain their solid structure once inside the body. Once in place, they form a compact scaffold that gradually connects to the host's circulatory system.
Over time, blood vessels grow into the graft area, keeping the hepatocytes healthy. "The new blood vessels formed right next to the hepatocytes, which is why they were able to survive," said lead author and MIT postdoc Vardhman Kumar. "They were able to get the nutrients delivered right to them, they were able to function the way they're supposed to, and they produced the proteins that we expect them to."
The injected cells and the microsphere structure kept on working for the entire eight-week run of the test. That is a meaningful result. The aim of the experiment was to restore the function of hepatocytes, which filter blood, synthesise and store protein, and transform carbohydrates, without the need for open surgery. The liver performs around 500 essential functions in the human body, making it among the most difficult organs to replicate or bypass.
The case for pursuing this line of research is straightforward. More than 10,000 Americans with chronic liver disease are on a transplant waitlist, and there are not enough donated organs for all of them. Many people with liver failure are also not eligible for a transplant because they are not healthy enough to tolerate major surgery. Australia faces an analogous problem. Transplant Australia records around 260 liver transplants performed each year, against a waiting list of some 1,850 people across all organ types. An injectable alternative that could restore partial liver function, or tide a patient over until a donor organ becomes available, would address a genuine gap in the system.
Kumar described the approach as creating "an engineered niche for cell transplantation", explaining that cells injected without the microsphere scaffolding would not integrate efficiently with the host, whereas the spheres allow hepatocytes to localise and connect to the host circulation much faster. This is the core technical advance: earlier attempts to inject hepatocytes directly into the body had failed because the cells dispersed and died before establishing a blood supply.
Advocates for greater public investment in regenerative medicine will find encouragement here. The technique, if it scales to humans, could reduce the healthcare system's dependence on the organ donation pipeline, which is structurally constrained. In 2024, around 1,630 of the 89,000 Australians who died in hospitals did so in circumstances where organ donation could even be considered. No policy setting can substantially expand that pool. A treatment that sidesteps the need for a donor entirely represents a different order of solution.
There are genuine reasons for caution, though, and they deserve to be stated plainly. With the current version of this technology, patients would likely need to take immunosuppressive drugs, though the researchers are exploring the possibility of developing hepatocytes that could evade the immune system, or using the hydrogel microspheres to deliver immunosuppressants locally. The ongoing requirement for immune suppression carries its own clinical risks and costs. The team acknowledged that the mouse results pave the way for human-scale testing, but that will require future work, and it is not clear if any is planned. No human trials have been announced, and the path from a promising mouse study to a clinically approved therapy typically takes a decade or more.
Patient advocates and bioethicists have also raised broader questions about equitable access to regenerative therapies. Novel biotechnologies tend to be expensive at first, and there is a legitimate concern that treatments developed in well-funded research universities could remain out of reach for health systems serving lower-income populations. The MIT team addressed this directly, arguing that "injectable, self-assembling niches represent a significant step toward regenerative treatments that are more scalable and accessible to patients who may not receive a donor organ." Scalability is, of course, easier to claim in a paper than to deliver in a manufacturing context.
What the research does establish, credibly, is a proof of concept. The INSITE system solved a problem that had stalled hepatocyte transplantation research for years: keeping injected cells alive and functional long enough to be useful. After injection, the cells remained viable and able to secrete specialised proteins into the host circulation for the full eight weeks of the study, suggesting the therapy could potentially work as a long-term treatment for liver disease. That is a foundation worth building on, with appropriate scrutiny at each stage.
For Australia's research and health policy community, the study is a reminder of what publicly funded basic science can produce. The research was funded by the National Cancer Institute, the National Institutes of Health, the Wellcome Leap HOPE Programme, a National Science Foundation Graduate Research Fellowship, and the Howard Hughes Medical Institute. The question of whether Australian research bodies should be collaborating on or funding analogous work is one that health policymakers and the Organ and Tissue Authority would do well to consider. The transplant waiting list is not going to shrink on its own.